

The Heart, the Kidney, and SGLT2 Inhibition: From Clinical Trials to Patient Care



This event is not part of the official Scientific Sessions 2020 as planned by the AHA Committee on Scientific Sessions Program.

Target Audience: This activity was developed for clinicians who manage patients with, or at risk for heart failure (HF), or chronic kidney disease (CKD).

Educational Grant: Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

Accreditation and Credit Designation Statements: Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits[™] through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits[™] from organizations accredited by the ACCME.

Date: Saturday, November 14, 2020

Time: 5:00 – 6:30 pm CST

Faculty:



Mikhail Kosiborod, MD
(Program Chair)



John McMurray, MD



Marc Sabatine, MD, MPH



Robert Toto, MD

Please join Chair Dr. Mikhail Kosiborod, and faculty members Dr. John McMurray, Dr. Marc Sabatine, and Dr. Robert Toto as they:

- Describe the effects of SGLT2 inhibitors on HF-related outcomes
- Interpret the evidence for SGLT2 inhibitors from clinical trials in patients with CKD with and without diabetes
- Discuss practical considerations regarding the use of SGLT2 inhibitors

Disclosure Statement:

It is the policy of Voxmedia to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose any significant financial, other interest or relationship (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only then may faculty receive approval to participate, and are expected to contribute evidence-based material and information. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis etc. All information submitted will be peer-reviewed.